Defeat GBM Research Collaborative By The Numbers

Halfway through its five-year, \$10 million commitment, the Collaborative is bringing forth a host of both new therapeutic targets as well as drugs of interest to be evaluated in the clinic.



1,000+ Drugs screened for potential effectiveness against GBM tumors in laboratory model

- **75,000**...combinations of compounds tested across different subtypes of GBM tumors
- 71...New laboratory models created, characterized, and validated to be used in drug testing
- 16...Potential new drugs/treatment approaches of interest identified for GBM
 - **8...**Potential new drugs/drug combinations prioritized for further preclinical to clinical advancement
 - 4...Compounds identified as near-term clinical candidates
- **29...**Papers and reviews published by Defeat GBM-funded researchers in high-impact scientific/medical journals
 - **300+...**The number of times these papers have been cited by other papers in the field
- 19... Novel targets for new treatment strategies identified
- 7...Potential new biomarkers identified to help predict and monitor patient response to GBM treatments
- 6... Areas identified as ripe for continued discovery/scientific efforts